文献速递类风湿关节炎

基线特征对传统合成改善病情抗风湿药应答不足的类风湿关节炎患者巴瑞替尼治疗应答的影响

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
PubMed 文献 · RMD Open · 2018-01-13

基于两项III期试验(RA-BEAM与RA-BUILD)的汇总事后分析,评估基线特征对巴瑞替尼4mg治疗csDMARDs应答不足类风湿关节炎患者疗效与安全性的影响。结果显示无论人口学及基线疾病特征如何,巴瑞替尼4mg均显示疗效,ACR20应答的OR值多倾向于巴瑞替尼优于安慰剂。结论认为基线特征未实质性影响巴瑞替尼4mg的临床应答。

要点

  • 巴瑞替尼4mg的疗效不受患者人口学及基线疾病特征实质性影响。
  • ACR20应答的OR值主要倾向于巴瑞替尼优于安慰剂。
  • 65岁以上患者安全性事件更常见,但巴瑞替尼4mg与安慰剂间相似。

核心结论

  • 基线特征未实质性影响csDMARDs应答不足类风湿关节炎患者对巴瑞替尼4mg的临床应答。

研究设计与样本

  • 对RA-BEAM(NCT01710358)与RA-BUILD(NCT01721057)两项III期试验的汇总数据进行事后分析。
  • RA-BEAM中甲氨蝶呤应答不足患者随机接受安慰剂、巴瑞替尼4mg或阿达木单抗40mg。
  • RA-BUILD中对至少1种csDMARDs应答不足患者随机接受安慰剂或每日一次巴瑞替尼2mg或4mg。
  • 两项研究人群均为生物制剂改善病情抗风湿药(bDMARDs)初治。
  • 主要终点为第12周美国风湿病学会20%改善(ACR20)应答率。

主要发现

  • 无论患者人口学及基线疾病特征如何,巴瑞替尼4mg治疗均观察到疗效。
  • ACR20应答的OR值主要倾向于巴瑞替尼优于安慰剂。
  • 在基于高敏C反应蛋白的28关节疾病活动度评分、简化疾病活动指数评分≤11及影像学进展等其他结局上,巴瑞替尼4mg无论基线特征如何均显示优于安慰剂的应答。
  • 65岁以上患者安全性事件更常见,但巴瑞替尼4mg与安慰剂患者间相似。

关键数值与推荐

  • 主要终点为第12周ACR20应答率。
  • 临床与安全性结局评估于第12周,影像学结局评估于第24周,比较巴瑞替尼4mg与安慰剂治疗患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We analysed the effects of baseline characteristics on the safety and efficacy of baricitinib in patients with rheumatoid arthritis (RA) with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) from two phase III trials. METHODS: In RA-BEAM (NCT01710358), patients with inadequate response to methotrexate were randomised to placebo, baricitinib 4 mg or adalimumab 40 mg. RA-BUILD (NCT01721057) patients had inadequate response to ≥1 csDMARDs and were randomised to either placebo or once-daily baricitinib (2 or 4 mg). Both study populations were naïve to biologic DMARDs (bDMARDs). Primary end point for both studies was American College of Rheumatology 20% improvement (ACR20) response at week 12. Pooled data from the two trials were analysed post hoc based on select subgroups defined by age, previous csDMARD use, baseline RA disease activity, etc, with assessment of clinical and safety outcomes at week 12 and radiographic outcomes at week 24 for the baricitinib 4 mg and placebo-treated patients. RESULTS: Efficacy was observed with baricitinib 4 mg treatment irrespective of patient demographics and baseline disease characteristics. ORs primarily favoured baricitinib over placebo in the ACR20 response. In other outcomes such as Disease Activity Score for 28 joints based on high-sensitivity C reactive protein levels, Simplified Disease Activity Index score ≤11 and radiographic progression, baricitinib 4 mg showed better responses than placebo regardless of baseline characteristics. Safety events were more common in patients over 65 years, but similar between baricitinib 4 mg and placebo patients. CONCLUSION: Baseline characteristics did not substantially affect clinical response to baricitinib 4 mg in patients with RA with inadequate response to csDMARDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kremer JM, Schiff M, Muram D, et al. Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. RMD Open. 2018. PMID: 29479473. doi:10.1136/rmdopen-2017-000581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。